Advertisement
Advertisement
CNTA
Centessa Pharmaceuticals plc - ADR
39.58
USDSponsored
-0.03
-0.08%
May 13, 15:58 UTC -4
Closed
Pre-Market
39.63
+0.05
+0.14%
CNTA Earnings Reports
Positive Surprise Ratio
CNTA beat 11 of 20 last estimates.
55%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
--
/-$0.42
Implied change from Q1 26 (Revenue/ EPS)
--
/-19.23%
Implied change from Q2 25 (Revenue/ EPS)
--
/+10.53%
Centessa Pharmaceuticals plc - ADR earnings per share and revenue
On May 05, 2026, CNTA reported earnings of -0.52 USD per share (EPS) for Q1 26, missing the estimate of -0.40 USD, resulting in a -28.65% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.18% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of -0.42 USD, with revenue projected to reach -- USD, implying an decrease of -19.23% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
May 13, 2026 For Q4 26
Estimate
-$24.25
Actual
$44.19
Surprise
+282.20%
Relmada Therapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.19
Actual
-$0.22
Surprise
-10.61%
Aquestive Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.13
Actual
-$0.07
Surprise
+49.96%
Altimmune, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.24
Actual
-$0.18
Surprise
+27.18%
Prelude Therapeutics Incorporated
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.25
Actual
-$0.13
Surprise
+48.68%
Unicycive Therapeutics, Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.51
Actual
-$0.54
Surprise
-4.49%
Karyopharm Therapeutics Inc.
Report Date
May 14, 2026 For Q1 26
Estimate
-$1.45
Actual
-$1.24
Surprise
+14.90%
Journey Medical Corporation Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.07
Actual
-$0.08
Surprise
-1.14%
Verrica Pharmaceuticals Inc. Common Stock
Report Date
May 12, 2026 For Q1 26
Estimate
-$0.38
Actual
-$0.41
Surprise
-5.92%
PolyPid Ltd. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.44
Actual
-$0.35
Surprise
+20.81%
FAQ
What were Centessa Pharmaceuticals plc - ADR's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Centessa Pharmaceuticals plc - ADR reported EPS of -$0.52, missing estimates by -28.65%, and revenue of $0.00, 0% as expectations.
How did the market react to Centessa Pharmaceuticals plc - ADR's Q1 2026 earnings?
The stock price moved down -0.18%, changed from $39.67 before the earnings release to $39.60 the day after.
When is Centessa Pharmaceuticals plc - ADR expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for Centessa Pharmaceuticals plc - ADR's next earnings report?
Based on 8
analysts, Centessa Pharmaceuticals plc - ADR is expected to report EPS of -$0.42 and revenue of -- for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement